10 June 2021

Dear world: meet ELOF1 – the newly discovered core factor in the TC-NER pathway

Bianca-Olivia Nita

Bianca-Olivia Nita

Damaged DNA is a problem for cells. DNA replication and transcription are hampered if the DNA template is damaged. Moreover, accumulating DNA damage is one of the hallmarks of cancer. Luckily our cells are equipped with machineries to fix damaged DNA. One of those is the transcription-coupled nucleotide excision repair (TC-NER) pathway, which removes UV induced damage. Until now, we only knew three core factors that could recognize DNA damage-stalled RNA polymerase: CSA, CSB and UVSSA. Using CRISPR/Cas9 technology Oncode Investigator Jurgen Marteijn’s new research has identified a fourth core factor, called ELOF1. The results of this research are now published in Nature Cell Biology.

DNA damage can be removed when it blocks the transcription machinery, which transcribes DNA into RNA. ‘We refer to that pathway as transcription-coupled nucleotide excision repair (TC-NER)’, says Marteijn. ‘We basically knew three core factors that recognize that the RNA polymerase is blocked at sites of DNA damage: CSA, CSB, and UVSSA, of which the latter was discovered in my lab back in 2012. And now we added ELOF1 as the fourth factor in this TC-NER pathway’ he adds. While linked to aging, recent insights show that this repair pathway also protects against genome instability. Furthermore, this pathway plays an important role in clearing DNA damage induced by chemotherapeutics. It thereby helps to make sure our bodies don’t experience too much side effects of chemotherapy, like neurotoxicity.

Riding the DNA train

So, how does this latter work? In a cell there are many processes that use DNA as a template. It is a bit like having multiple trains driving towards each other or driving in the same direction at different speeds: eventually they can collide. And that can happen with the replication machinery and the transcription machinery in dividing cells. Usually this is well coordinated, so that a piece of DNA is never both replicated and transcribed at the same time. In comes the new study of Marteijn’s group. Without ELOF1, these conflicts start appearing upon DNA damage more often and have a nasty effect: an accumulation of mutations and genome instability, both risk factors for developing cancer.

Credit: Esther Morren, Erasmus MC

According to Marteijn’s findings, ELOF1 has three important functions which prevent this from happening. ´Firstly, ELOF1 is a so-called transcription elongation factor binding to RNA pol II´, Marteijn explains. ‘While RNA polymerase II is the major protein that does the hard work during transcription, it needs auxiliary factors like ELOF1 to make the process efficient. Secondly, ELOF1 is a crucial factor in TC-NER - it is indispensable the actual repair process. Thirdly, and perhaps the thing that surprised us the most, is the role of ELOF1 in protecting cells against transcription replication conflicts. So, how does this latter work? In a cell there are many processes that use DNA as a template. It is a bit like having multiple trains driving towards each other or driving in the same direction at different speeds: eventually they can collide. And that can happen with the replication machinery and the transcription machinery in dividing cells. Usually this is well coordinated, so that a piece of DNA is never both replicated and transcribed at the same time. In comes the new study of Marteijn’s group. Without ELOF1, these conflicts start appearing upon DNA damage more often and have a nasty effect: an accumulation of mutations and genome instability, both risk factors for developing cancer. It makes ELOF1 a multifunctional protein which plays a key role in genome integrity at multiple levels.’

All four TC-NER factors are important. Yet, there is a reason why ELOF1 was found only now. Historically, in the DNA repair field, important proteins are identified by analysing genetic material of patients that show DNA repair defects. It is how CSA and CSB pathways were identified in the 90’s, using cells originating from TC-NER deficient Cockayne syndrome patients. Then in 2012, Jurgen Marteijn’s lab identified UVSSA being defective in patients with UV sensitivity syndrome. But ELOF1 links to an essential gene – without it, life is not possible - and that most likely explains that there were not any patients identified with mutations in this gene. The journey that led to its discovery started with an Oncode collaboration with Rene Bernards’ lab, performing CRISPR/Cas9 whole genome screens. ‘This collaboration and the technology breakthrough were the basis of this discovery and made the difference. In the traditional way with patient groups, most likely we would have never found this gene’ says Marteijn. ‘Although this is basic research, it gives insight into how this important repair machinery works and protects against genome instability. This helps us to better understand the origins of cancer’ he concludes.

Other News

Oncode Icons Round tumor growth theme 1
Oncode collaboration: mobilizing innate leukocytes to attack tumors
In 2021, Oncode Institute organized brainstorm sessions to come up with ideas for cross-disciplinary synergies between Oncode researchers to tackle difficult challenges in cancer research. A group of Oncode Investigators from different institutes* came up with an exciting new idea requiring their collaboration to become successful. This launched a new Oncode Accelerator Project: mobilizing innate leukocytes to attack tumors
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Oncode about icon copy 13
Oncode spin-off Immagene announces seed investment round to progress novel Immuno-Oncology therapeutics
Immagene B.V., a spin-off of the Netherlands Cancer Institute (NKI) and Oncode Institute, today announces it has raised a seed financing round to advance its next-generation precision Immuno-Oncology (IO) therapeutics. BOM Brabant Ventures joined as a new investor with additional support from existing investors Swanbridge Capital and Oncode Oncology Bridge Fund.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
20211104 oncode kit 45
More than science: highlights from the Oncode CGC Annual Conference
Did you attend Oncode’s Annual Conference at the Royal Tropical Institute at the beginning of November? If not, you’ve been missing out. Was it the wide variety of topics presented by a great mix of experts who delivered their knowledge with passion and insight, both in person and online? Was it the energy and joy that came from being able to get together face to face, right before a new lockdown? In any case, make sure to check out the highlights!
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>